Do Mild Traumatic Brain Injuries Double the Risk of Dementia?
A large retrospective study in veterans finds that even brain injuries that cause no loss of consciousness come with a twofold higher risk of developing all-cause dementia.
274 RESULTS
Sort By:
A large retrospective study in veterans finds that even brain injuries that cause no loss of consciousness come with a twofold higher risk of developing all-cause dementia.
The two datasets reveal almost identical cognitive decline in prodromal AD, the stage targeted by secondary prevention trials.
Even at below threshold levels, cortical amyloid can drive cognitive decline, tau accumulation.
Two tau PET tracers flag brain areas that accumulate tangles, without background labeling in the choroid plexus. However, pesky off-target binding was seen in the meninges.
The antioxidant ebselen promotes disulfides in SOD1, restores dimerization, and prevents protein misfolding.
Biogen showed results from clinical trials of anti-Aβ and anti-α-synuclein antibodies at the American Academy of Neurology annual meeting.
Researchers take first steps on road to targeting disease-causing APP mutations and amyloid processing.
The drug had no effect on any clinical measure, while there were side effects such as rashes, insomnia, and thoughts of suicide.
In an AD mouse model, a deficit in specialized mediators prevented microglia from tempering inflammation and clearing Aβ. Time to learn about resolvins?
Two enormous epidemiological studies strengthen the link between head injuries and neurodegenerative disease.
People with inflammatory bowel disease are at higher risk for Parkinson’s—but not if they take anti-inflammatory medication.
Thirty-five reviews cover two decades of Alzheimer’s research.
Three genome-wide association studies, including the largest-ever thanks to UK Biobank, reveal 13 new AD risk loci. They implicate APP processing in LOAD, and further highlight inflammation and lipid metabolism.
Transportins, methylation, and RNA all regulate LLPS and the behavior of pathogenic RNA-binding proteins.
At AAT-AD/PD, scientists said an α-synuclein PET tracer is headed into trials. And marmosets model PD behaviors better than rodents. (Spoiler alert: They kick their partners while they sleep.)